RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 Significant HbA1c Reduction With Empagliflozin/Linagliptin Combination
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 4
SP 14
OP 14
DO 10.1177/1559897715581835
UL http://mdc.sagepub.com/content/15/4/14.1.abstract
AB Over a 24-week period, a combination of empagliflozin/linagliptin for the treatment of type 2 diabetes produced significant reductions in HbA1c compared with linagliptin and with empagliflozin 10 mg, but not empagliflozin 25 mg. This randomized trial suggests that this approach could be a more efficient way to achieve glycemic control.